RxDoctor Payments Data

Ashley Norris, DO

Internal Medicine · Glasgow, KYNPI 1679737209

Payments from drug & device makers

$6,789in general payments, 2019–2025

Across 516 payments — averaging $13.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$918
  • Novo Nordisk$875
  • Pfizer$613
  • Novartis$464
  • Merck$453
  • Lilly USA, LLC$342
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$6,73699%
  • Education$521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,789 in reported general payments places this provider in the 90th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$348,486
Medicare patients
568
Services billed
20,121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide424$492,974
JardianceEmpagliflozin317$320,248
MounjaroTirzepatide176$207,553
EliquisApixaban236$198,927
TrulicityDulaglutide113$134,809
JanuviaSitagliptin Phosphate147$113,030
LinzessLinaclotide121$93,826
Tresiba Flextouch U-200Insulin Degludec57$84,491
FarxigaDapagliflozin Propanediol82$69,603
XareltoRivaroxaban86$63,648
MyrbetriqMirabegron114$47,013
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog32$36,655
ProliaDenosumab17$28,324
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr50$23,238
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$20,852

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$875$492,974424 claims
Lilly USA, LLCMounjaro, Trulicity$342$342,362289 claims
Boehringer IngelheimJardiance$223$320,248317 claims
PfizerEliquis$613$198,927236 claims
MerckJanuvia, Janumet$453$128,843161 claims
AstraZenecaFarxiga, Brilinta, Breztri Aerosphere, Bevespi Aerosphere$183$110,082142 claims
AbbVieLinzess, Synthroid$918$103,413298 claims
Johnson & JohnsonXarelto, Invokana$203$81,517122 claims
GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta$157$51,57088 claims
Astellas Pharma US IncMyrbetriq$126$47,013114 claims
AmgenProlia$332$28,32417 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$211$12,26926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Glasgow

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →